NAT-treated patient with NGMGCT in our institute. Here we summarize the current status of these patients and discuss the delivery of NAT in patients with these tumors.
Methods

Patient Characterizations
The study population consisted of 14 consecutive patients in whom NGMGCTs received NAT originally designed at our institute. Our earlier report 13 included 11 patients; on reevaluation of our NAT protocol, we excluded one earlier patient who subsequently underwent partial tumor removal at another hospital. The current study population comprised 14 patients including 10 we described previously and 4 with newly diagnosed NGMGCTs. The pretreatment diagnosis was primarily based on the serum level of tumor markers; within cases of equivocal tumor marker elevation, a biopsy was performed. An elevated AFP level (> 100 ng/ml) was considered suggestive of mixed germ cell tumor including yolk sac tumor or embryonal carcinoma components. In the presence of elevated HCG, b-HCG (> 100 mIU/ml), and/or AFP levels we suspected mixed germ cell tumor including components of immature teratoma or choriocarcinoma, and if both HCG and b-HCG were markedly increased (> 10 5 mIU/ ml), we made a pretreatment diagnosis of choriocarcinoma. Because it is possible that AFP is negative and HCG and/or b-HCG are slightly increased (< 100 mIU/ml) in germinoma or germinoma with syncytiotrophoblastic giant cells, a biopsy was performed in those cases and there was no patients with NGMGCTs.
Treatment Plans
We delivered NAT consisting of combined chemoand radiotherapy followed by the complete resection of the residual tumor. Chemotherapy was primarily based on platinum: a combination of cisplatin (20 ) for 5 consecutive days. Usually these cycles were repeated every 4 weeks for a total of 2 or 3 cycles before surgery. Almost all patients experienced toxicity manifesting as myelosuppression; patients with leukocytopenia were injected with GCSF, and patients with thrombocytopenia received platelet transfusions to maintain the chemotherapy schedule. Radiotherapy consisted of 24-40 Gy directed at the whole brain or at an area covering all ventricles (lateral, third, and upper fourth), followed by a 15-to 30-Gy boost to the tumor site. If the CSF was cytologically positive for tumor cells, we delivered 30 Gy to the whole spine. As a result of this series, the patients received radiotherapy of at least 44.5 Gy (range 44.5-60 Gy) for the tumor site and at least 24 Gy (range 24-40 Gy) for the whole brain or extended local area (all ventricles are covered). Radiotherapy and chemotherapy were usually started on the same day, although in some patients the initiation of radiotherapy was postponed. To assess the response to NAT, we ascertained that the serum tumor marker level was in the normal or near-normal range; residual tumors were resected completely. Patients received postoperative chemotherapy every 2-3 months for 1-2 years.
Evaluation of NAT
To assess the tumor size after treatment, we used RECIST (Response Evaluation Criteria in Solid Tumors) guidelines. We evaluated NAT toxicity using the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3). 26 All resected tumors were studied pathologically; the presence of viable cells was determined by routine H & E and MIB-1 staining. To determine survival and the patient's QOL, we analyzed progression-free and overall survival times with the KaplanMeier method and the Karnofsky Performance Scale. We also recorded whether the patients were able to work, get married, and whether they required HRT.
Results
Response to NAT
In 3 patients a complete response and in 9 a partial response manifested; in 2 there was no change. Although imaging studies failed to yield evidence of a response in the latter 2 cases, the post-NAT serum levels of AFP, HCG, and b-HCG were normalized in all 14 patients ( Table 1) .
Toxicity of NAT
In the course of initial chemo-and radiotherapy and during maintenance chemotherapy, 12 patients developed leukocytopenia (Grade 4 in 7 patients; Grade 3 in 4; and Grade 2 in 1), and 9 patients developed thrombocytopenia (Grade 4 in 6; and Grade 1 in 3). Granulocyte colonystimulating factor was subcutaneously injected in 10 patients; 6 required platelet transfusions ( Table 2) .
In some patients a reduction in the preoperative chemotherapy doses was required. Although the full dose was delivered in 3 patients, the start of chemotherapy was postponed in 2 and 1 required autologous hematopoietic cell rescue. In the other patients, the preoperative chemotherapy dose was reduced by 20%-50%. Controversy continues to surround the start of radiotherapy because simultaneous chemo-and radiotherapy may induce severe bone marrow suppression, and therefore, radiotherapy is administered before or after chemotherapy. We delivered radiotherapy and chemotherapy concurrently; both treatments were usually started in the same week. In Case 8, at the patient's request, the start of chemotherapy was postponed for 35 days after the beginning of radiotherapy.
Radiation-induced secondary tumors, an adverse effect of radiotherapy, developed in 3 patients (Cases 3-5) (Fig. 1) , 2 of whom (Cases 4 and 5) required no treatment. However, in Case 3 a glioblastoma developed 10 years after NAT for NGMGCT, and despite chemotherapy for glioblastoma, the patient died 1 year after the diagnosis of his secondary tumor. Brain infarction was observed in one patient (Case 1) 16 years after initial treatment. Angiography demonstrated the left posterior cerebral artery, which was included in the radiation field of the initial treatment. It was considered that the brain infarc- tion was the adverse effect of radiotherapy. The patient's symptoms-mild weakness and paresthesia of the right hand-were completely recovered after a few months. Sagittal sinus thrombosis associated with seizures and left hemiparesis was observed in one patient (Case 2) immediately after the completion of a second course of cisplatin and etoposide; the symptoms resolved in 4 weeks after initiation of heparin therapy (Table 3) .
Surgery
In 11 of the 14 patients residual tumors were radiologically confirmed after NAT; 10 of these tumors were completely resected. In the other patient (Case 12) a small piece of the residual tumor that was tightly attached to a vein was left in place. The postoperative course in 7 patients was uneventful, but 2 suffered transient hemiparesis, 1 developed 
Pathological Evaluation of the Resected Tumors
Of 11 resected residual tumors, 3 were histologically diagnosed as mature teratomas, 3 were composed of mesenchymal fibrous tissues, 2 of necrotic tissue, and the other 3 harbored viable tumor cells within teratomatous and mesenchymal tissues ( Table 1 ). The MIB-1 labeling index of the latter 3 tumors ranged from 5.7%-60%; the index did not exceed 5% in nontumoral tissues.
Neuroimaging findings were predictive of the tumor histology in Case 10; after NAT and before surgery, the patient in Case 10 developed a new enhanced nodule. In 2 cases we detected viable tumor cells in the residual tissues: a multicystic enhanced mass in one and an irregular enhanced lesion in the other. In 8 patients neuroimaging detected no viable tumor cells in the residual tissue after NAT, but these preoperative findings were equivocal, indicating that neuroimaging findings were not always predictive of the presence of viable tumor cells.
Patient Survival
The follow-up duration ranged from 1.2 to 22.2 years. Of 14 patients, 11 were alive at the time of writing, without recurrence. Overall survival was determined with the Kaplan-Meier method (Fig. 2) .
Two patients died of tumor recurrence.
In one (Case 6), an 11-year-old boy with Down syndrome, complete remission was obtained, but 3.7 years after the initial treatment the tumor recurred and was revealed as a gadolinium-enhanced lesion at the bilateral anterior horn of the lateral ventricles. His serum HCG and b-HCG levels increased by 75.4 and 72.1 mIU/ml, respectively. After 3 courses of chemotherapy with carboplatin, bleomycin, and etoposide, the tumor disappeared and both serum the HCG and b-HCG levels were normalized. However, 7 months after the second treatment b-HCG increased by 168.5 mIU/ml. Chemotherapy with paclitaxel, ifosfamide, and carboplatin produced severe myelosuppression, and the patient died 5 years after the initial treatment.
In another patient (Case 12) who had undergone partial tumor removal and maintenance chemotherapy, complete remission was radiologically documented; the patient's serum AFP level became negative. However, 7 months later there was CSF dissemination on the cerebellar surface and the patient's AFP level increased by 188 ng/ml. Two courses of chemotherapy with paclitaxel, ifosfamide, and cisplatin produced a reduction in the tumor * CSH = chronic subdural hematoma; difficult = impossible to work or have no job; HS = high school; JHS = junior high school; OK = working normally; RIT = radiation-induced tumor. † Down syndrome was not the adverse effect of the therapy. size, and the patient's serum AFP level again normalized. Severe myelosuppression rendered a third course of chemotherapy impossible, and 3 months after the second round of chemotherapy, diffuse CSF dissemination manifested on the cerebral surface. The patient died 16 months after his initial treatment.
We documented tumor recurrence in only 2 patients, and the event-free survival period ranged from 0.6 to 22.2 months (median 11.1, mean 11.7 months). We have sometimes observed recurrence after 5 years in patients with germinoma, but we have never documented recurrence in patients with NGMGCTs 5 years after initial treatment.
One patient (Case 3) with a germ cell tumor who received NAT and in whom complete remission occurred for 10 years developed glioblastoma as a secondary radiation-induced tumor. He died of glioblastoma 11 years after the initial treatment.
Quality of Life
The issues surrounding the QOL were essentially based on the clinical records. At the last follow-up, the KPS score was 90 or higher in 9 patients and 70 in 2 patients. One patient (Case 10), whose current KPS score is 90 and who has mild mental disability due to a basal ganglia lesion, graduated from high school. Another patient (Case 2), who was treated for a suprasellar lesion, graduated from a school for handicapped children; he is now 24 years old and unable to work because of moderate mental disability. The patient in Case 7 harbored a suprasellar and cerebral hemisphere lesion; she developed right frontal cerebral hemorrhage from an arteriovenous malformation and underwent surgery at the age of 20 years. All 7 living patients with suprasellar lesions needed HRT (Table 1 ). All 4 patients who were younger than 12 years when the tumor was diagnosed required growth hormone, and none suffered tumor recurrence during the follow-up period. At the time of this writing, all patients were older than 18 years, and only 3 were able to get jobs. The site of the initial tumor in these 3 patients was pineal, and none currently receive HRT. No patients with suprasellar or basal ganglia lesion were able to get a "normal" job, although we think that appropriate HRT would enable them to work. It is not clear how tumors located in the suprasellar region damage neuroendocrine functions. We also investigated the highest educational background in the patients with NGMGCT. Four patients had graduated from college (Table 3 ), but 1 of 4 died of the radiation-induced secondary glioblastoma. Surprisingly, the site of the tumor in these 4 patients was pineal, and none of the patients with suprasellar region or basal ganglia lesion could go to college. None of the patients in this study are married (Table 3) .
Discussion
Controversy continues to surround the management of patients with intracranial germ cell tumors, and although different protocols have been used to address NGMGCTs, their prognosis remains unsatisfactory. 2, 12, 20 Matsutani et al. 18 reported that 9 of 10 patients in whom NGMGCT resection was followed by chemo-and radiotherapy suffered tumor recurrence. Radical tumor removal followed by chemo-and radiotherapy was attempted in 18 patients by Robertson et al. 21 Their 5-year event-free and total survival rates were 67% and 74%, respectively. Four patients suffered tumor recurrence and progression, however: 1 recurrence at the primary site and 3 outside the radiation field, without local recurrence. In 18 patients, Baranzelli and colleagues 2 followed chemotherapy alone with resection of the residual tumor. They used radiotherapy only in patients in whom viable residual tumors were present. Tumors recurred in 12 of 13 patients in whom radiotherapy was not undertaken, leading Baranzelli and colleagues to conclude that NGMGCTs were not curable with conventional chemotherapy alone and that focal radiotherapy should be part of the treatment.
Based on these findings we posited that surgery followed by adjuvant chemo-and radiotherapy fails to improve the outcome in patients with NGMGCTs and that surgery followed by adjuvant therapy increases the risk of tumor cell dissemination. Therefore, we developed a new treatment strategy comprising neoadjuvant (preoperative) combined chemo-and radiotherapy followed by resection of residual tumors. The aim of this treatment strategy is 2-fold: a reduction in the tumor volume to minimize the risk of operative morbidity and a decrease in the number of viable tumor cells before surgery to prevent intraoperative CSF dissemination.
In the present series, the 5-year event-free and total survival rates were 86% and 93%, respectively. In 1 patient (Case 6) the tumor recurred 3.7 years after he underwent the initial treatment, and he died 5.1 years after the initial treatment. Although he experienced a complete remission, his tumor recurred at the original site (the left basal ganglia and bilateral anterior horn of the lateral ventricles). The reason for the recurrence was unclear, but his Down syndrome may have played a contributing role. 6 We speculate that DNA repair activity was low in the cells due to Down syndrome, 23 and thus, new tumor cells may have arisen under the same circumstances. Radiation in the tumor area may contribute to the development of the tumor. Another patient (Case 12) underwent partial removal of the lesion because the tumor adhered tightly to a deep vein. Because the resected tissue contained viable tumor cells, we posit that viable tumor cells were left behind by the partial resection, and despite 3 consecutive chemotherapy courses of ifosfamide, cisplatin, and etoposide, the patient suffered tumor recurrence 8 months later. This case suggests that NGMGCTs may contain cells resistant to chemo-and radiotherapy and that consecutive surgeries might be effective. Calaminus et al. 5 reported on NGMGCTs in 41 patients enrolled in the German prospective protocol MAKEI 89; the authors concluded that neither complete nor incomplete resection had a significant effect on survival. Nonetheless, despite our experience with Case 12, we conclude that our NAT protocol requires the complete resection of the NGMGCT to obtain the best possible treatment outcomes.
Adverse Effects of NAT
The interval between the start of NAT and resection of residual tumors ranged from 2 to 19 months depending on the time required for tumor marker normalization and for recovery from bone marrow suppression. In our protocol, because chemo-and radiotherapy are usually started simultaneously, almost all patients manifested bone marrow suppression (Table 2) , and 10 (71%) of 14 required GCSF injections and 6 (43%) required platelet transfusions. Although the start timing of chemotherapy and radiotherapy remains controversial, we recommend that they be started simultaneously and as soon as possible because the tumor cells have a malignant potential and may disseminate easily within the CSF space.
The provision of spinal radiotherapy is also controversial 8 because it induces severe bone marrow suppression compared with radiotherapy of the brain only. Only 2 of our patients underwent spinal radiotherapy, and spinal dissemination was not a factor in tumor recurrence, and the need for spinal radiotherapy, as a means of preventing spinal dissemination, remains unclear. As another adverse effect of radiotherapy, 3 patients developed radiation-induced secondary tumors; 25,28 2 were benign (meningioma and cavernous angioma) and 1 was a glioblastoma (Fig. 1) . Although radiotherapy may cause severe adverse effects, we assume it is absolutely necessary for the control of NG-MGCT.
Quality of Life
The reported median survival in patients with NG-MGCT is less than 2 years and fewer than 30% live as long as 5 years postdiagnosis. 1, 10 In our series, 13 of 14 patients survived for longer than 5 years, and although 2 patients died at 11.5 and 5.0 years postdiagnosis, respectively, the other 11 are alive and free of tumor recurrence. Only 3 patients were able to hold a job; the other 11 did not work and could not attend a regular school. In the 3 patients with a high QOL the tumor location was pineal, and the patients did not require HRT. Because many patients with pituitary adenomas, craniopharyngiomas, and germinomas need HRT and hold regular jobs, HRT does not necessarily result in a poor QOL. 22 However, none of our patients receiving HRT could work a regular job or attend a regular school. We posit that the impairment of hypothalamic function is more severe in patients with NGMGCTs than other diseases and that radio-and chemotherapy to control these tumors may damage normal brain function.
Although our NAT protocol to treat patients with NGMGCTs yielded excellent survival outcomes, the posttreatment QOL of these patients must be improved.
Conclusions
We consider our NAT protocol for NGMGCT to be highly effective in relation to survival, but there are several QOL issues that need to be resolved.
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